Vittal K. Vasista
Net Worth

Last updated:

What is Vittal K. Vasista net worth?

The estimated net worth of Mr. Vittal K. Vasista is at least $8,534,107 as of 19 Mar 2024. He owns shares worth $1,135,330 as insider, has earned $2,191,977 from insider trading and has received compensation worth at least $5,206,800 in null.

What is the salary of Vittal K. Vasista?

Mr. Vittal K. Vasista salary is $650,850 per year as Senior Vice President & Chief Financial Officer in null.

How old is Vittal K. Vasista?

Mr. Vittal K. Vasista is 57 years old, born in 1968.

What stocks does Vittal K. Vasista currently own?

As insider, Mr. Vittal K. Vasista owns shares in one company:

Company Title Shares Price per share Total value
(RGNX) Senior Vice President & Chief Financial Officer 135,160 $8.4 $1,135,330

What does do?

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

RGNX logo
RGNX
$8.4

Vittal K. Vasista insider trading

Mr. Vittal K. Vasista has made 53 insider trades between 2017-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 120,000 units of RGNX stock on 7 Feb 2019. As of 19 Mar 2024 he still owns at least 135,160 units of RGNX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Employee Stock Option (Right to Buy) 20,041 $3.76 $75,354
Option
Common Stock 20,041 $3.76 $75,354
Option
Employee Stock Option (Right to Buy) 35,000 $0.85 $29,750
Option
Common Stock 35,000 $0.85 $29,750
Sale
Common Stock 2,400 $30.24 $72,574
Sale
Common Stock 17,280 $35.19 $608,031
Sale
Common Stock 400 $35 $14,000
Sale
Common Stock 2,400 $31.26 $75,012
Sale
Common Stock 468 $30 $14,040
Sale
Common Stock 4,332 $30.01 $129,990
Option
Common Stock 29,900 $0.85 $25,415
Option
Employee Stock Option (Right to Buy) 29,900 $0.85 $25,415
Option
Employee Stock Option (Right to Buy) 10,000 $0.85 $8,500
Option
Common Stock 10,000 $0.85 $8,500
Sale
Common Stock 252 N/A N/A
Sale
Common Stock 11,093 N/A N/A
Sale
Common Stock 4,200 N/A N/A
Sale
Common Stock 5,241 N/A N/A
Sale
Common Stock 10,998 N/A N/A
Sale
Common Stock 3,376 N/A N/A
Sale
Common Stock 21,124 N/A N/A
Sale
Common Stock 14,916 N/A N/A
Sale
Common Stock 22,584 N/A N/A
Sale
Common Stock 14,950 N/A N/A
Option
Common Stock 3,259 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,259 N/A N/A
Sale
Common Stock 500 N/A N/A
Option
Employee Stock Option (Right to Buy) 500 N/A N/A
Option
Common Stock 500 N/A N/A
Option
Common Stock 2,500 N/A N/A
Option
Employee Stock Option (Right to Buy) 2,500 N/A N/A
Sale
Common Stock 7,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,000 N/A N/A
Sale
Common Stock 12,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Sale
Common Stock 3,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Sale
Common Stock 14,806 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,000 N/A N/A
Sale
Common Stock 300 N/A N/A
Sale
Common Stock 2,394 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 3,068 N/A N/A
Option
Employee Stock Option (Right to Buy) 120,000 N/A N/A
Option
Common Stock 120,000 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 $61.22 $459,128
Sale
Common Stock 7,500 N/A N/A
Option
Common Stock 53,741 N/A N/A
Option
Employee Stock Option (Right to Buy) 53,741 N/A N/A
Sale
Common Stock 53,741 N/A N/A
Option
Common Stock 19,677 $8.43 $165,779
Option
Employee Stock Option (Right to Buy) 19,677 N/A N/A
Option
Employee Stock Option (Right to Buy) 19,677 $8.43 $165,779
Sale
Common Stock 19,677 N/A N/A
Option
Common Stock 19,677 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 $59.26 $444,450
Option
Common Stock 30,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 30,000 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 $49.97 $374,753
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 60,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 60,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 30,000 N/A N/A
Option
Common Stock 30,000 N/A N/A
Sale
Common Stock 4,994 N/A N/A
Sale
Common Stock 6 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 3,040 N/A N/A
Sale
Common Stock 3,100 N/A N/A
Sale
Common Stock 3,100 N/A N/A
Sale
Common Stock 3,100 N/A N/A
Sale
Common Stock 3,100 N/A N/A

key executives

executives and other stock owners filed with the SEC: